Active Clinical Trials at OOS
All Clinical Trials
ASTX030-01 (ASTEX)
Tumor site:
Hematologic (MDS, CMML, AML)
Description:
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Available at:
More info:
BDX-00146 (BIODESIX)
Tumor site:
Lung
Description:
An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)
Available at:
More info:
Bespoke 20-041-NCP (BESPOKE)
Tumor site:
Colorectal
Description:
An Observational Study of ctDNA Guided Therapy in Colorectal Cancer.
Available at:
More info:
Bespoke IO 20-043-NCP (BESPOKE)
Tumor site:
Lung, Melanoma, Colorectal
Description:
A BESPOKE Study of ctDNA Guided Immunotherapy for Non-Small cell lung cancer, Melanoma, and Colorectal cancer.
Available at:
More info:
EQ132-201 (EQRx)
Tumor site:
Breast
Description:
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer
Available at:
More info:
LOXO-BTK-20019 (J2N-OX-JZNM)
Tumor site:
Mantle Cell Lymphoma
Description:
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Available at:
More info:
Mirati KRYSTAL 7 (Mirati 849-007)
Tumor site:
Lung (NSCLC)
Description:
Phase 2 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)
Available at:
More info:
Notes:
NCT: 04613596
Mirati KRYSTAL 12 (Mirati 849-012)
Tumor site:
Lung (NSCLC)
Description:
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)
Available at:
More info:
Notes:
NCT: 04685135
Prevalence (64091742PCR0002)
Tumor site:
Prostate
Description:
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer. Observational study.
Available at:
More info:
Page 1 of
Page: